Literature DB >> 20428671

15d-PGJ(2) modulates acute immune responses to Trypanosoma cruzi infection.

Wellington F Rodrigues1, Camila B Miguel, Javier E Lazo Chica, Marcelo H Napimoga.   

Abstract

The acute phase of Trypanosoma cruzi infection is associated with a strong inflammatory reaction in the heart characterised by a massive infiltration of immune cells that is dependent on the T. cruzi strain and the host response. 15d-PGJ(2) belongs to a new class of anti-inflammatory compounds with possible clinical applications. We evaluated the effects of 15d-PGJ(2) administered during the acute phase of T. cruzi infection in mice. Mice were infected with the Colombian strain of T. cruzi and subsequently treated with 15d-PGJ2 repeatedly for seven days. The inflammatory infiltrate was examined by histologic analysis. Slides were immunohistochemically stained to count the number and the relative size of parasite nests. Infection-induced changes in serum cytokine levels were measured by ELISA. The results demonstrated that treatment with 15d-PGJ(2) reduced the inflammatory infiltrate in the skeletal muscle at the site of infection and decreased the number of lymphocytes and neutrophils in the blood. In addition, we found that 15d-PGJ(2) led to a decrease in the relative volume density of amastigote nests in cardiac muscle. T. cruzi-infected animals treated with 15d-PGJ(2) displayed a statistically significant increase in IL-10 levels with no change in IFN-gamma levels. Taken together, we demonstrate that treatment with 15d-PGJ(2) in the acute phase of Chagas disease led to a controlled immune response with decreased numbers of amastigote nests, as measured by the volume density.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20428671     DOI: 10.1590/s0074-02762010000200005

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  7 in total

1.  Oxidative stress fuels Trypanosoma cruzi infection in mice.

Authors:  Claudia N Paiva; Daniel F Feijó; Fabianno F Dutra; Vitor C Carneiro; Guilherme B Freitas; Letícia S Alves; Jacilene Mesquita; Guilherme B Fortes; Rodrigo T Figueiredo; Heitor S P Souza; Marcelo R Fantappié; Joseli Lannes-Vieira; Marcelo T Bozza
Journal:  J Clin Invest       Date:  2012-06-25       Impact factor: 14.808

Review 2.  Are reactive oxygen species always detrimental to pathogens?

Authors:  Claudia N Paiva; Marcelo T Bozza
Journal:  Antioxid Redox Signal       Date:  2013-10-26       Impact factor: 8.401

Review 3.  Bioactive lipids in Trypanosoma cruzi infection.

Authors:  Fabiana S Machado; Shankar Mukherjee; Louis M Weiss; Herbert B Tanowitz; Anthony W Ashton
Journal:  Adv Parasitol       Date:  2011       Impact factor: 3.870

4.  Administration of artinm lectin reduces the severity of the acute phase infection with Trypanosoma cruzi.

Authors:  Camila Botelho Miguel; Thiago Aparecido da Silva; Wellington Francisco Rodrigues; Patrícia Kellen Martins Oliveira-Brito; Maria Cristina Roque-Barreira; Javier Emílio Lazo-Chica
Journal:  FASEB Bioadv       Date:  2021-01-25

5.  Role of PPARs in Trypanosoma cruzi Infection: Implications for Chagas Disease Therapy.

Authors:  Eugenia Hovsepian; Federico Penas; Gerardo A Mirkin; Nora B Goren
Journal:  PPAR Res       Date:  2012-02-09       Impact factor: 4.964

6.  Pyridinecarboxylic Acid Derivative Stimulates Pro-Angiogenic Mediators by PI3K/AKT/mTOR and Inhibits Reactive Nitrogen and Oxygen Species and NF-κB Activation Through a PPARγ-Dependent Pathway in T. cruzi-Infected Macrophages.

Authors:  Federico Nicolás Penas; Davide Carta; Ágata Carolina Cevey; María Jimena Rada; Azul Victoria Pieralisi; María Grazia Ferlin; María Elena Sales; Gerardo A Mirkin; Nora Beatriz Goren
Journal:  Front Immunol       Date:  2020-01-09       Impact factor: 7.561

Review 7.  Inflammatory and Pro-resolving Lipids in Trypanosomatid Infections: A Key to Understanding Parasite Control.

Authors:  Rodrigo A López-Muñoz; Alfredo Molina-Berríos; Carolina Campos-Estrada; Patricio Abarca-Sanhueza; Luis Urrutia-Llancaqueo; Miguel Peña-Espinoza; Juan D Maya
Journal:  Front Microbiol       Date:  2018-08-21       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.